Maxim Group Maintains Their Buy Rating on Navidea (NAVB)

By Carrie Williams

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Navidea (NAVBResearch Report), with a price target of $3.00. The company’s shares closed last Monday at $0.80.

According to, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -18.2% and a 21.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Hancock Jaffe Laboratories, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Navidea with a $3.50 average price target, which is a 297.7% upside from current levels. In a report issued on March 2, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.84 and a one-year low of $0.12. Currently, Navidea has an average volume of 156.4K.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NAVB in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.